For decades, cancer immunotherapy has had one dirty little secret.
The soldiers run out.
T-cell therapies? Brilliant against blood cancers. Almost useless against solid tumors.
Macrophages? Great at infiltrating tumors… but they vanish from the bloodstream almost as fast as you inject them.
So scientists at USC asked a different question.
What if we don't send soldiers into battle at all?
What if we send the factory?
Meet the GMP — granulocyte-monocyte progenitor.
It's the cell that gives birth to macrophages and other immune warriors.
Until now, nobody could keep these precursors alive and multiplying outside the body. They'd mature. They'd die. Game over.
The USC team, led by Prof. Qi-Long Ying, cracked the code.
They found the exact culture conditions that let GMPs self-renew indefinitely — dividing endlessly while staying in that magical "precursor" state.
Published in Cell. And it's a genuinely big deal.
The team went one step further.
They took these self-renewing GMPs and engineered them with CAR technology — the same trick that made T-cell therapy famous — to hunt down cancer.
Then they injected them straight into the bone marrow.
Not the bloodstream.
The factory floor.
From there, the GMPs set up shop and started pumping out cancer-killing immune cells… on repeat.
In animal trials, these engineered GMPs took down:
🩸 CD19-positive leukemia — the classic blood cancer target
🧫 HER2-positive solid tumors — the ones T-cells struggle with
🛡️ Bacterial infections, as a bonus — immunity got a full upgrade
Survival rates jumped significantly.
And because the cells work in both mouse and human systems, the translation path is real.
Today's cell therapies are one-shot deals.
You infuse. The cells fade. The cancer often comes back.
A self-renewing precursor flips that model on its head.
👉 One dose. Continuous supply. Off-the-shelf potential.
Ying himself called out the shock of it: the long-held belief was that only true blood stem cells could self-renew long-term. GMPs weren't supposed to do this.
They do.
That single discovery may unlock a new class of therapies — not just for cancer, but for infectious disease, autoimmune conditions, maybe more.
We've spent years building better soldiers.
USC just built a factory that never sleeps.
That's all for now!
